Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Gebru, Tamirat ^a,b   Hailu, Asrat ^c   Kremsner, Peter G ^b,d   Kun, Jürgen F J ^d   Grobusch, Martin P ^b,e  

^a HARAMAYA UNIVERSITY   (Ethiopia)

^b ALBERT SCHWEITZER HOSPITAL   (Gabon)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYTOCHROME B;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; ETHIOPIA; GABON; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MALARIA; MICROBIAL GENETICS; MOLECULAR GENETICS; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PROTOZOAL INFECTION;

ANIMALS; ATOVAQUONE; CODON; CYTOCHROMES B; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; MUTATION; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGUANIL;

EID: 33845406273     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-112     Document Type: Article

References (41)

1. Meyer CG, May J, Arez AP, Gil JP, do Rosario V: Genetic diversity of Plasmodium falciparum: asexual stages. Trop Med Int Health 2002, 7:395-408.
2. Krungkrai J: The multiple roles of the mitochondrion of the-malarial parasite. Parasitology 2004, 129:511-524.
3. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB: Malarone (atovaquone and proguanil hydrochloride): a reviewof its clinical development for treatment of malaria. Malarone-Clinical Trials Study Group. Am J Trop Med Hyg 1999, 60:533-541.
4. Fry M, Pudney M: Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4¢-chlorophenyl) cyclohexyl]-3-hydroxy- 1,4-naphthoquinone (566C80). Biochem Pharmacol 1992, 43:1545-1553.
5. Mather MW, Darrouzet E, Valkova-Valchanova M, Cooley JW, McIntosh MT, Daldal F, Vaidya AB: Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J Biol Chem 2005, 280:27458-27465.
6. Suswam E, Kyle D, Lang-Unnasch N: Plasmodium falciparum: The effects of atovaquone resistance on respiration. Exp Parasitol 2001, 98:180-187.
7. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999, 33:704-711.
8. Srivastava IK, Vaidya AB: A mechanism for the synergisticanti-malarial action of atovaquone and proguanil. Antimicr Agents Chemother 1999, 43:1334-1339.
9. Murphy AD, Lang-Unnasch N: Alternative oxidase inhibitorspotentiate the activity of atovaquone against Plasmodium falciparum. Antimicrob Agents Chemother 1999, 43:651-654.
10. Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, abroad spectrum antiparasitic drug, collapses mitochondrial membranepotential in a malarial parasite. J Biol Chem 1997, 272:3961-3966.
11. Kovacs JA: Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992, 340:637-638.
12. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock J, Falloon J, Feinberg J, LaFon S, Rogers M, Sattler F: Comparison of atovaquone (566C80) with trimethoprim sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. New Engl J Med 1993, 328:1521-1527.
13. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DBA, Canfield CJ: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62-66.
14. Chiodini PL, Conlon CP, Hutchinson DB, Farquhar JA, Hall AP, Peto TE, Birley H, Warrell DA: Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995, 36:1073-1078.
15. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q: Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000, 44:2100-2108.
16. Kuhn S, Gill MJ, Kain KC: Emergence ofatovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg 2005, 72:407-409.
17. Canfield CJ, Pudney M, Gutteridge WE: Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995, 80:373-381.
18. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG: Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511-1514.
19. Hogh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Gunther M, Joubert I, Kain KC, Shaw D, Roskell NS, Chulay JD, Malarone International Study Team: Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Lancet 2000, 356:1888-1894.
20. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD, Malarone International Study Team: Atovaquone-proguanilversus mefloquine for malaria prophylaxis in nonimmune travelers:Results from a randomized, doubleblind study. Clin Infect Dis 2001, 33:1015-1021 [http://www.journals.uchicago.edu/CID/ journal/issues/v33n7/010125/010125.text.html?erFrom=-5188934061545476792Guest- fn1].
21. McKeage K, Scott L: Atovaquone/proguanil: a review of itsuse for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003, 63:597-623.
22. Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, Roskell NS, Hedgley C, De Boever EH, Miller GB: Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travellers: results of an international, randomized, open-label study. Clin Infect Dis 2004, 38:1716-1723.
23. Thybo S, Gjorup I, Ronn AM, Meyrowitsch D, Bygberg IC: Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J Travel Med 2004, 11:220-223.
24. Shretta R, Brugha R, Robb A, Snow RW: Sustainability, affordability, and equity of corporate drug donations: the case of Malarone. Lancet 2000, 355:1718-1720.
25. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG: Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998, 351:709-713.
26. Gebru-Woldearegai T, Asrat H, Grobusch MP, Kun JFJ: Molecular surveillance of mutations in DHFR and DHPS genes of Plasmodium falciparum in Ethiopia. Am J Trop MedHyg 2005, 73:1131-1134.
27. Kun JFJ, Lehman LG, Lell B, Schmidt-Ott JR, Kremsner PG: Low-dose treatment with sulfadoxine-pyrimethaminecombinations selects for drug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 1999, 43:2205-2208.
28. [http://www.mbio.ncsu.edu/BioEdit/bioedit.html]. [last accessed on 8 August 2006]
29. Giao PT, de Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA: Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam. Ann Trop Med Parasitol 2003, 97:575-580.
30. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis MM: In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 1997, 56:315-317.
31. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G: Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002, 1:1.
32. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, daCunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J, European Network on Surveillance of Imported Infectious Diseases: Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 2004, 190:1541-1546.
33. Schwöbel B, Alifrangis M, Salanti A, Jelinek T: Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003, 2:5.
34. Meshnick SR, Trumpower B: Multiple cytochrome b mutations-may cause atovaquone resistance (comment). J Infect Dis 2005, 191:822.
35. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T: Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J 2004, 3:14.
36. Thapar MM, Gil JP, Bjorkman A: In vitro recrudescence of Plasmodium falciparum parasites suppressedto dormant state by atovaquone alone and in combination with proguanil. Trans R Soc Trop Med Hyg 2005, 99:62-70.
37. Basco LK: Molecular epidemiology of malaria in Cameroon. xvii. Baseline monitoring of atovaquone-resistant plasmodium falciparum by in vitro drug assays and cytochcrome b gene sequence analysis. Am J Trop Med Hyg 2003, 69:179-183.
38. Muehlen M, Schreiber J, Ehrhardt S, Otchwemah R, Jelinek T, Bienzle U, Mockenhaupt FP: Short communication: prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. Trop Med Int Health 2004, 9:361-363.
39. Pimentel S, Nogueira F, Benchimol C, Quinhentos V, Bom J, Varandas L, do Rosario V, Bernadino L: Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Malar J 2006, 5:30.
40. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J: Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 2006, 57:110-115.
41. Berry A, Senescau A, Levievre J, Benoit-Vical F, Fabre R, Marchou B, Magnaval JF: Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med Hyg 2006, 100:986-988.